Medication info
Citaro M Sustained Release Tablets 50/1000 mg (Sitagliptin Hydrochloride Hydrate, Metformin Hydrochloride)

Citaro M Sustained Release Tablets 50/1000 mg (Sitagliptin Hydrochloride Hydrate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Hanlim Pharmaceutical Co., Ltd.
Appearance
Bright green, oval-shaped sustained release film-coated tablets with a convex surface on both sides
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202202081 · Approved 2022.05.17 · Insurance code 645306890

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and not split, crushed, ground, or chewed. Cases have been reported in which the drug was incompletely dissolved and excreted in the stool. It is not known whether the material excreted in the stool contained the active ingredients. If a patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take one 100/1000 mg extended-release tablet once daily. Patients taking this drug as 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment experience who cannot achieve adequate blood glucose control with monotherapy, or for patients who cannot achieve adequate blood glucose control with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Patients Who Must Not Receive This Drug). 2. Patients receiving metformin: - For patients who cannot achieve adequate blood glucose control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug as 50/1000 mg extended-release tablets once daily. 3. Patients unable to achieve adequate blood glucose control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should take into account the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment Because this drug contains metformin, it should not be administered to patients with hepatic impairment (see Precautions for Use, 2. Patients Who Must Not Receive This Drug).

Ingredients

Manufacturer
Hanlim Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is used as an adjunct to diet and exercise to help control blood sugar in patients with type 2 diabetes. By combining sitagliptin and metformin, it effectively aids in managing blood sugar levels, thereby improving blood sugar levels and alleviating symptoms of diabetes. Therefore, good therapeutic effects can be expected when this medication is taken continuously along with lifestyle modifications.

How to take

Adult dose

In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and not split, crushed, ground, or chewed. Cases have been reported in which the drug was incompletely dissolved and excreted in the stool. It is not known whether the material excreted in the stool contained the active ingredients. If a patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take one 100/1000 mg extended-release tablet once daily. Patients taking this drug as 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment experience who cannot achieve adequate blood glucose control with monotherapy, or for patients who cannot achieve adequate blood glucose control with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Patients Who Must Not Receive This Drug). 2. Patients receiving metformin: - For patients who cannot achieve adequate blood glucose control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug as 50/1000 mg extended-release tablets once daily. 3. Patients unable to achieve adequate blood glucose control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should take into account the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment Because this drug contains metformin, it should not be administered to patients with hepatic impairment (see Precautions for Use, 2. Patients Who Must Not Receive This Drug).

Precautions

This medication contains sitagliptin and metformin, which are diabetes treatments that help control blood sugar. While using this medication, allergic reactions may occur, so if symptoms such as skin rashes, hives, or difficulty breathing appear, usage should be discontinued immediately and medical advice sought. There is also a risk of developing acute pancreatitis, which is inflammation of the pancreas; therefore, symptoms such as abdominal pain, nausea, or vomiting should be reported to medical personnel immediately. Patients with severe renal impairment or serious conditions such as heart failure, acute myocardial infarction, or sepsis should not use this medication and should also discontinue use before and after examinations using iodinated contrast media. This medication is not recommended for use in pregnant or nursing women, or children under 18 years of age, as its safety and efficacy have not been established. During treatment with this medication, rare but potentially fatal side effects such as lactic acidosis should be monitored, and if symptoms like muscle pain, difficulty breathing, weakness, or abdominal pain occur, immediate hospital care is necessary. Symptoms of hypoglycemia may also occur, so it is important to eat regularly and avoid excessive exercise or alcohol consumption. Particularly, elderly patients or those with deteriorating kidney function should undergo regular kidney function tests and, if necessary, dosage adjustments or discontinuation should be considered. This medication may interact with other hypoglycemic agents or drugs, so it is essential to inform healthcare providers of any current medications being used. In cases of planned surgery, severe infections, or dehydration, administration should be temporarily halted and restarted once the condition improves. Finally, regular blood sugar monitoring and blood tests to check kidney function and vitamin B12 levels are necessary during treatment.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 15 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and debilitating arthralgia
  • vesicular-like pemphigus
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Bright green, oval-shaped sustained release film-coated tablets with a convex surface on both sides

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.